- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT01961583
[18F]Fluciclatide PET Imaging of Pazopanib Response
February 27, 2016 updated by: Jin-Sook Ryu, Asan Medical Center
Evaluation of [18F]FluciclatidePositron Emission Tomography For the Prediction of Response to Pazopanib In Patients With Metastatic Renal Cell Carcinoma: An Exploratory Study
Positron emission tomography (PET) is a non-invasive imaging tool for monitoring functional and metabolic responses of biological events with specific radiotracer in vivo.
The PET tracer [18F]Fluciclatide is an 18F radiolabeled small peptide containing the RGD (arginine-glycine-aspartate) tri-peptide, which preferentially binds with high affinity to αvβ3 and αvβ5 integrins.
αvβ3-integrins are expressed at low levels on epithelial cells and mature endothelial cells but are expressed at high levels on activated endothelial cells in the neo-vasculature of a range of tumors and it also may regulate angiogenesis.
If pazopanib acts mainly on active angiogenetic tumors, the quantitative uptake of [18F]Fluciclatide can be used to predict the effect of this antiangiogenic drug.
The investigators expected the baseline tumor uptake in [18F]Fluciclatide to be able to predict treatment response, and planned a study of [18F]FluciclatidePET for patients with metastatic RCC who received pazopanib systemic therapy.
Study Overview
Detailed Description
Subjects will receive treatment with pazopanib at a dose of 800 mg orally once daily.
[18F]Fluciclatide imagings will be taken 2 times; 1) before systemic therapy (at baseline), 2) at one week after starting of Pazopanib.
However, If the target lesion on the baseline PET cannot be discriminated compared to the background activity, the 2nd PET will not be done.
Response evaluation by CT will be performed at baseline, at 6 week, at 12 week and every 8 weeks thereafter until the end of treatment.
RECIST1.1 criteria for response will be applied.
Patient will be treated with Pazopanib until there is disease progression, unacceptable toxicity or withdrawal of patient consent.
Study Type
Interventional
Enrollment (Actual)
12
Phase
- Phase 2
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Locations
-
-
Songpa-gu
-
Seoul, Songpa-gu, Korea, Republic of, 138-736
- Asan Medical Center
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
20 years and older (Adult, Older Adult)
Accepts Healthy Volunteers
No
Genders Eligible for Study
All
Description
Inclusion Criteria:
- Histologically confirmed renal cell carcinoma, stage IV patient.
- The tumor mass ≥1.5cm in diameter that is planned to receive Pazopanib as systemic antiangiogenic therapy.
- Pretreatment CT with or without contrast within 4 weeks prior to the first 18F-Fluciclatide PET scan.
- Evidence of unidimensionally measurable lesion(s) by RECIST criteria version 1.1.
- No prior systemic anti-angiogenic therapy for metastatic disease; prior antiangiogenic therapy used as an adjuvant therapy is allowed if it is completed 6 or more months before study enrollment.
- Male or female aged over 20 years
- Be ambulatory and have an Eastern Cooperative Oncology Group (ECOG) performance status 0-2.
- Have a life expectancy of at least 3 months.
- Adequate medical condition in the judgment of the investigator
- Be willing and able to comply with the protocol for the duration of the study.
- Be willing and able to implement effective contraceptive practice
- Give written informed consent prior to study-specific screening procedures, with the understanding that the patient has the right to withdraw from the study at any time, without prejudice.
Exclusion Criteria:
- Received another IMP within 30 days before the first administration of 18F-Fluciclatide injection.
- Inability to perform 18F-Fluciclatide PET imaging studies due to physical inability or claustrophobia.
- Intra-hepatic tumor only (without extra-hepatic tumor)
- Chemotherapy within 2weeks, or received radiotherapy to the region of the target lesion, surgery of target lesion within 2 weeks prior to the first 18F-Fluciclatide PET scan
- Pregnant, nursing women or patients with reproductive potential without contraception.
- Current treatment on another therapeutic clinical trial(except Pazopanib study)
- Any patients with known allergy to the GE health care product or any or its excipients should be excluded from the study
- Any condition that, in the opinion of the investigator, would compromise the well-being of the subject or the study or prevent the subject from meeting or performing study requirements.
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: Diagnostic
- Allocation: N/A
- Interventional Model: Single Group Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: Drug; 18F-Fluciclatide
18F-Fluciclatide, 0.14 mCi/kg (not to exceed 10 mCi), IV(in the vein) administration
|
Baseline 18F-Fluciclatide PET imaging will be obtained before starting of Pazopanib therapy(within 7 days). Subsequent 18F-Fluciclatide PET should be performed on 7 days after Pazopanib therapy
Other Names:
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Baseline 18F-Fluciclatide PET SUV
Time Frame: Prior to starting Pazopanib treatment
|
The difference of the baseline 18F-Fluciclatide PET SUV between responders and non-responders by RECIST criteria after Pazopanib therapy
|
Prior to starting Pazopanib treatment
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
The difference of 18F-Fluciclatide PET parameters (% change of SUV) between responders and non-responders by RECIST criteria
Time Frame: 7±1 days after Pazopanib treatment
|
7±1 days after Pazopanib treatment
|
|
Progression free survival more than 6 month
Time Frame: More than 6 month after 1st PET scan
|
Progression free survival defined as time from PET scan to the date of death, recurrence or progression
|
More than 6 month after 1st PET scan
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Sponsor
Collaborators
Investigators
- Principal Investigator: Jin-Sook Ryu, MD. PhD., Asan Medical Center
Publications and helpful links
The person responsible for entering information about the study voluntarily provides these publications. These may be about anything related to the study.
Helpful Links
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start
September 1, 2013
Primary Completion (Anticipated)
April 1, 2016
Study Completion (Anticipated)
April 1, 2016
Study Registration Dates
First Submitted
October 7, 2013
First Submitted That Met QC Criteria
October 10, 2013
First Posted (Estimate)
October 11, 2013
Study Record Updates
Last Update Posted (Estimate)
March 1, 2016
Last Update Submitted That Met QC Criteria
February 27, 2016
Last Verified
February 1, 2016
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- 2013-0382
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Kidney Neoplasm
-
National Cancer Institute (NCI)CompletedNeoplasm Metastasis | Neoplasm | Kidney DiseaseUnited States
-
Association of Urologic Oncology (AUO)IAG-N at German Cancer Association (Deutsche Krebsgesellschaft e. V.)Not yet recruiting
-
Johns Hopkins UniversityNational Comprehensive Cancer NetworkRecruitingKidney NeoplasmUnited States
-
Azienda Socio Sanitaria Territoriale degli Spedali...UnknownGlomerular Filtration Rate | Nephrectomy | Kidney NeoplasmItaly
-
National Cancer Institute (NCI)TerminatedSarcoma | Breast Neoplasm | Lung Neoplasm | Kidney NeoplasmUnited States
-
Mayo ClinicCompleted
-
National Cancer Institute (NCI)CompletedLymphoma | Breast Cancer | Neoplasm Metastasis | Ovarian Cancer | Kidney NeoplasmUnited States
-
Allena PharmaceuticalsCompletedNephrolithiasis | Kidney Stones | Hyperoxaluria | Secondary HyperoxaluriaUnited States
-
Zhen Wang, MDAmerican Cancer Society, Inc.RecruitingRenal Cell Cancer | Kidney Neoplasm | Benign Kidney NeoplasmUnited States
-
Allena PharmaceuticalsCompletedNephrolithiasis | Kidney Stones | Hyperoxaluria | Secondary Hyperoxaluria | Dietary HyperoxaluriaUnited States
Clinical Trials on 18F-Fluciclatide
-
GE HealthcareQuintiles, Inc.; i3 Statprobe; BIAFFIN GmbH & Co. KG (Biomolecular Interaction...CompletedSarcoma | Renal Cell Carcinoma | Breast Cancer | Head and Neck Cancer | Lung Cancer | Solid Tumors | High Grade GliomasUnited States
-
National Cancer Institute (NCI)WithdrawnKidney Neoplasms
-
M.D. Anderson Cancer CenterGE HealthcareWithdrawn
-
GE HealthcareCompletedMelanoma | Sarcoma | Lung Cancer | High-grade Glioma | Head & Neck CancerUnited States
-
National Cancer Institute (NCI)WithdrawnMultiple Myeloma | Monoclonal Gammopathy of Undetermined Significance | Smoldering Multiple Myeloma
-
Oxford University Hospitals NHS TrustGE Healthcare; University of OxfordTerminated
-
National Cancer Institute (NCI)National Institutes of Health Clinical Center (CC); GE HealthcareWithdrawnRenal Cell Carcinoma | Cervical Cancer | Lung Cancer | Colon Cancer | Uterine CancerUnited States
-
Genentech, Inc.Completed
-
Adam BrickmanNational Institute on Aging (NIA)Completed
-
Chang Gung Memorial HospitalRecruitingProgressive Supranuclear PalsyTaiwan